Multiomics identifies tumor-intrinsic SREBP1 driving immune exclusion in hepatocellular carcinoma by Jie Chen, Arjun Singh, Riyue Bao, Jason John Luke, Sarah Newman, Aatur Singhi, Carsten Krieg, Ryan Augustin, Aofei Li, Brian Isett, Rebekah E Dadey, Ruxuan Li, Jake Griner, Joseph A Manning, Satdarshan P Monga, David A A Geller, Ioannis K Zervantonakis

Get full text

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716... by Dirk Schadendorf, Caroline Robert, Reinhard Dummer, Luis de la Cruz-Merino, Paolo A Ascierto, John M Kirkwood, Georgina V Long, Jacek Mackiewicz, Richard A Scolyer, Piotr Rutkowski, Jean-Jacques Grob, Jason John Luke, Michele Del Vecchio, Mizuho Kalabis, Adnan Khattak, Matteo S Carlino, Yujie Zhao, Alexander Eggermont, Vanna Chiarion Sileni, Clemens Krepler

Get full text

Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy by Dirk Schadendorf, Celeste Lebbe, Teresa Amaral, Benjamin Weide, Mariaelena Capone, Gabriele Madonna, Lucia Festino, Reinhard Dummer, Domenico Mallardo, Paolo A Ascierto, Piotr Rutkowski, Jason John Luke, Kilian Wistuba-Hamprecht, Mitchell P Levesque, Roberta Turiello, Elva Morretta, Maria Chiara Monti, Rosa Azzaro, Laurence Imhof, Marc Chevrier, Antje Sucker, Aldo Pinto, Silvana Morello

Get full text

Radiomic analysis of patient and interorgan heterogeneity in response to immunotherapies and BRAF-targeted therapy in metastatic melanoma by Riyue Bao, Yana G Najjar, Diwakar Davar, John M Kirkwood, Jason John Luke, Sarah Newman, Hassane M Zarour, Afsaneh Amouzegar, Rivka R Colen, Murat Ak, Priyadarshini Mamindla, Serafettin Zenkin, Vishal Peddagangireddy, Sarah Behr, Alexandra G Tompkins, Zane N Gray, Rebekah E Dadey, Nasim Batavani, Nursima Ak, Taha Yasin Pak, Mohammadreza Amjadzadeh, Amy Goodman, Darcy L Ploucha, Curtis Tatsuoka

Get full text

First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors by Ignacio I Wistuba, Mamta Kalra, Linus Backert, Martin Wermke, Edwin R Parra, Jason John Luke, Apostolia M Tsimberidou, Sebastian Bunk, Mohammad B Hossain, Andrea Mayer-Mokler, Arun Satelli, Norbert Hilf, Steffen Walter, Cedrik M Britten, Van K Morris, Tobias A W Holderried, Winfried H Alsdorf, Katrin Wetzko, Borje S Andersson, Sandra Grund-Gröschke, Katrin Aslan, Anantha Marisetty, Swapna Satam, Jens Hukelmann, M Alper Kursunel, Karine Pozo, Andreas Acs, Melissa Baumeister, Claudia Wagner, Oliver Schoor, Ali S Mohamed, Delfi Krishna

Get full text